Summary

The global slide stainer market is valued at USD 4.3 billion in 2022 and is projected to reach USD 5.9 billion in 2027 at a CAGR of 6.8% from 2022 to 2027. The major factors driving the growth of this market are the high volume of cancer diagnoses, increasing cancer drug research, advancing healthcare infrastructure and expanding geriatric population. However, the high cost of the slide staining systems and the consolidation in the slide stainer system market are factors expected to restrain the growth of this market in the coming years.
“The reagents & kits segment accounted for the largest share of the slide stainer market in 2021.”
The slide stainer market by product is further segmented into the slide stainer market is segmented into reagents & kits, equipment, and consumables & accessories. The reagents & kits dominated the slide stainer products with the high usage of the reagent & kits in the diagnosis and research of various diseases such as cancer, infections and other chronic conditions. The lung pathology-related diagnosis and research-related studies have increased the volume of slide staining.
“The hematoxyline & eosin segment accounted for the largest share of the slide stainer market in 2021.”
The slide stainer market by technology is further segmented into the slide stainer market is segmented into hematoxylin & eosin, immunohistochemistry, in situ hybridization, cytology, microbiology, hematology, and special staining. The hematoxylin & eosin dominated the slide stainer products. Hematoxylin & eosin is the most used slide staining technique used for the diagnosis and research of cancer, infectious, and other chronic diseases.

“The disease diagnosis application segment is estimated to grow at a rapid rate during the forecast period.”
Based on application, the slide stainer market is segmented into disease diagnosis and medical research. In 2021, the disease diagnosis application accounted for the largest share of the slide stainer market and is projected to grow at the highest CAGR. The increasing cases of cancer, such as breast cancer, gastric cancer, lymphoma, etc., and infections. The prevalence of cancer and various infections is rising, which has boosted the growth rate of the application segment.

“Hospitals & diagnostics centers segment accounted for the largest share of end users of the slide stainer market in 2021.”
The end user segment of the slide stainer market is further segmented into hospitals and diagnostics centers, academic and research institutes, pharmaceutical and biotechnology companies, and other end users. The dominant share was accounted for by the hospitals and diagnostics centers segment in 2021, which was driven by the high volume of cancer slide staining due to the cancer biopsies, diagnosis and research. Also, the high burden of infections such as COVID-19 and their diagnosis have promoted the segment of the slide stainer end users.

“Asia Pacific is the fastest-growing regional market for slide stainer.”
In 2021, the slide stainer market was further divided into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America region ruled the market in 2021, followed by Europe. Although, the Asia Pacific region is expected to grow with the fastest growth rate during the forecast period of 2022 to 2027, with the improving healthcare infrastructure, medical investments, vast patient base of geriatric patients and increasing cases of cancer, infections and other chronic complications.

The breakdown of the primary participants’ profiles has been provided below:
• By Company Type: Tier 1: 31%, Tier 2: 46%, and Tier 3: 23%
• By Designation: C-level: 42%, Director-level: 26%, and Others: 32%
• By Region: North America: 35%, Europe: 30%, Asia Pacific: 21%, and Rest of the World: 14%

The key players operating in the slide stainer market include the following:
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Danaher Corporation (US)
• PHC Holdings Corporation (Japan)
• Thermo Fisher Scientific, Inc. (US)
• Merck KGAA (Germany)
• Agilent Technologies, Inc. (US)
• Abcam Plc. (UK)
• Becton, Dickinson and Company (US)
• Siemens Healthineers AG (Germany)
• Biocare Medical, LLC (US)
• Hardy Diagnostics (US)
• General Data Company (US)
• ELITechGroup (France)
• Biogenex (US)
• Histo-Line Laboratories (Italy)
• SLEE MEDICAL GmbH (Germany)
• Amos scientific Pty Ltd. (Australia)
• MEDITE Medical GMBH (Germany)
• Cellpath Ltd (UK)
• Diapath S.P.A. (Italy)
• Bio SB, Inc. (US)
• Rockland Immunochemicals, Inc. (US)
• Cell Signaling Technology, Inc. (US)
• Diagnostic BioSystems, Inc. (US)
• Dakewe Biotech Co., Ltd. (China)

Research Coverage
This report studies the slide stainer market based on product, application, technology, end user and region. The report also analyzes factors (drivers, restraints, opportunities, and challenges) affecting the market growth. It evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micromarkets with respect to their growth trends, prospects, and contributions to the total slide stainer market. The report forecasts the revenue of the market segments with respect to four major regions.

Reasons to Buy the Report:
The report provides insights on the following pointers:
• Market Penetration: Comprehensive information on the slide stainer offered by the top 17 players in the market. The report analyzes the slide stainer market by product and region.
• Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various slide stainers across key geographic regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the slide stainer market.
• Competitive Assessment: In-depth assessment of market shares and strategies of the leading players in the slide stainer market.

ページTOPに戻る

Table of Contents

1 INTRODUCTION 29
1.1 STUDY OBJECTIVES 29
1.2 MARKET DEFINITION 29
1.2.1 INCLUSIONS AND EXCLUSIONS 29
1.3 MARKET SCOPE 30
1.3.1 GEOGRAPHIC SCOPE 31
1.3.2 YEARS CONSIDERED 31
1.4 CURRENCY CONSIDERED 31
1.5 LIMITATIONS 32
1.6 MARKET STAKEHOLDERS 32
1.7 SUMMARY OF CHANGES 32
2 RESEARCH METHODOLOGY 34
2.1 RESEARCH DATA 34
FIGURE 1 RESEARCH DESIGN 34
2.1.1 SECONDARY DATA 35
2.1.1.1 Secondary sources 36
2.1.2 PRIMARY DATA 36
FIGURE 2 PRIMARY SOURCES 36
2.1.2.1 Key data from primary sources 37
2.1.2.2 Key industry insights 38
2.1.2.3 Breakdown of primary interviews 39
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY- AND DEMAND-SIDE PARTICIPANTS 39
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS 39
2.2 MARKET SIZE ESTIMATION 40
FIGURE 5 REVENUE SHARE ANALYSIS ILLUSTRATION: F. HOFFMANN-LA ROCHE AG 40
FIGURE 6 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH 41
2.2.1 GROWTH FORECAST 42
FIGURE 7 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 42
FIGURE 8 TOP-DOWN APPROACH 43
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 44
FIGURE 9 DATA TRIANGULATION METHODOLOGY 44
2.4 MARKET SHARE ANALYSIS 45
2.5 ASSUMPTIONS FOR THE STUDY 45
2.6 INDICATORS AND ASSUMPTIONS 46
2.7 RISK ASSESSMENT 46
TABLE 1 RISK ASSESSMENT 46
3 EXECUTIVE SUMMARY 47
FIGURE 10 SLIDE STAINER MARKET, BY PRODUCT, 2022 VS. 2027 (USD BILLION) 47
FIGURE 11 SLIDE STAINER MARKET, BY TECHNOLOGY, 2022 VS. 2027 (USD BILLION) 48
FIGURE 12 SLIDE STAINER MARKET, BY APPLICATION, 2022 VS. 2027 (USD BILLION) 48
FIGURE 13 SLIDE STAINER MARKET, BY END USER, 2022 VS. 2027 (USD BILLION) 49
FIGURE 14 GEOGRAPHIC SNAPSHOT: SLIDE STAINER MARKET 50
4 PREMIUM INSIGHTS 51
4.1 SLIDE STAINER MARKET OVERVIEW 51
FIGURE 15 RISING PREVALENCE OF CANCER TO DRIVE MARKET GROWTH 51
4.2 ASIA PACIFIC SLIDE STAINER MARKET: BY APPLICATION AND COUNTRY (2021) 52
FIGURE 16 DISEASE DIAGNOSTICS SEGMENT DOMINATED ASIA PACIFIC SLIDE STAINER MARKET, BY APPLICATION, IN 2021 52
4.3 GEOGRAPHIC MIX: SLIDE STAINER MARKET 52
FIGURE 17 NORTH AMERICA TO DOMINATE SLIDE STAINER MARKET DURING FORECAST PERIOD 52
4.4 SLIDE STAINER MARKET: GEOGRAPHIC SNAPSHOT 53
FIGURE 18 CHINA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 53
5 MARKET OVERVIEW 54
5.1 INTRODUCTION 54
5.2 MARKET DYNAMICS 54
FIGURE 19 SLIDE STAINER MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 54
5.2.1 DRIVERS 55
5.2.1.1 Rising prevalence of cancer 55
TABLE 2 INCREASING INCIDENCE OF CANCER, BY REGION, 2020 VS. 2030 VS. 2040 (MILLION) 55
TABLE 3 PROJECTED INCREASE IN GLOBAL NUMBER OF CANCER PATIENTS, 2015 VS. 2018 VS. 2035 56
5.2.1.2 Recommendations for cancer screening 56
5.2.1.3 Increasing healthcare expenditure 56
FIGURE 20 HEALTH EXPENDITURE PER CAPITA, 2010–2019 57
FIGURE 21 HEALTH EXPENDITURE (% OF GDP), 2010–2019 57
5.2.1.4 Rising geriatric population and subsequent growth in chronic and infectious disease prevalence 58
FIGURE 22 ESTIMATED INCREASE IN CANCER INCIDENCE (MILLION), 2020 VS. 2030 58
FIGURE 23 ESTIMATED CANCER DEATHS (MILLION), 2020 VS. 2030 58
5.2.1.5 Growing number of private diagnostic centers globally 59
5.2.1.6 Increasing automation in laboratories 59
5.2.1.7 Increasing use of AI in histopathology 59
5.2.2 RESTRAINTS 60
5.2.2.1 High equipment cost 60
 
5.2.3 OPPORTUNITIES 60
5.2.3.1 High-growth opportunities in emerging markets 60
FIGURE 24 GROWTH IN HEALTHCARE EXPENDITURE PER CAPITA IN BRICS COUNTRIES, 2012–2019 61
5.2.3.2 Increasing number of clinical trials pertaining to cancer drugs 61
5.2.4 CHALLENGES 61
5.2.4.1 Dearth of knowledgeable and skilled technicians 61
TABLE 4 NUMBER OF PATHOLOGISTS PER 100,000 POPULATION, BY COUNTRY, 2018 62
5.2.4.2 Product recalls 62
TABLE 5 INDICATIVE LIST OF PRODUCT RECALLS FOR SLIDE STAINING EQUIPMENT (2019–2022) 62
5.2.4.3 Availability of refurbished equipment 63
5.3 VALUE CHAIN ANALYSIS 63
FIGURE 25 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES 63
5.4 SUPPLY CHAIN ANALYSIS 64
FIGURE 26 DIRECT DISTRIBUTION—PREFERRED STRATEGY FOR PROMINENT COMPANIES 65
5.5 TECHNOLOGY ANALYSIS 65
5.6 PORTER’S FIVE FORCES ANALYSIS 66
5.6.1 THREAT OF NEW ENTRANTS 66
5.6.2 INTENSITY OF COMPETITIVE RIVALRY 66
5.6.3 BARGAINING POWER OF BUYERS 66
5.6.4 BARGAINING POWER OF SUPPLIERS 66
5.6.5 THREAT OF SUBSTITUTES 66
5.7 KEY STAKEHOLDERS AND BUYING CRITERIA 67
5.7.1 KEY STAKEHOLDERS IN BUYING PROCESS 67
FIGURE 27 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS FOR TOP 3 END USERS 67
TABLE 6 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS FOR TOP 3 END USERS (%) 67
5.7.2 BUYING CRITERIA 67
FIGURE 28 KEY BUYING CRITERIA FOR TOP 3 END USERS 67
TABLE 7 KEY BUYING CRITERIA FOR TOP 3 END USERS 68
5.8 REGULATORY LANDSCAPE 68
TABLE 8 INDICATIVE LIST OF REGULATORY AUTHORITIES GOVERNING SLIDE STAINING MARKET 68
5.9 PATENT ANALYSIS 70
5.10 KEY CONFERENCES AND EVENTS IN 2022–2023 71
TABLE 9 LIST OF CONFERENCES AND EVENTS 71
5.11 PRICING ANALYSIS 71
TABLE 10 PRICE RANGE FOR SLIDE STAINERS 71
5.12 TRADE ANALYSIS 72
TABLE 11 IMPORT DATA FOR HS CODE 847989, BY COUNTRY, 2017–2021 (USD MILLION) 72
TABLE 12 EXPORT DATA FOR HS CODE 847989, BY COUNTRY, 2017–2021 (USD MILLION) 72
5.13 ECOSYSTEM ANALYSIS 73
TABLE 13 ROLE IN ECOSYSTEM 73
FIGURE 29 KEY PLAYERS OPERATING IN SLIDE STAINER MARKET 74
5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 74
6 SLIDE STAINER MARKET, BY PRODUCT 75
6.1 INTRODUCTION 76
TABLE 14 SLIDE STAINER MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 76
6.2 REAGENTS AND KITS 76
TABLE 15 SLIDE STAINER MARKET FOR REAGENTS AND KITS, BY TYPE, 2020–2027 (USD MILLION) 76
6.2.1 STAINS 77
6.2.1.1 Staining is extensively used in diagnosis and research of carcinoma tissue samples 77
TABLE 16 SLIDE STAINER MARKET FOR STAINS, BY REGION, 2020–2027 (USD MILLION) 77
6.2.2 BLOCKING SERA AND REAGENTS 77
6.2.2.1 Blocking sera and reagents prevent nonspecific binding and reduce background noise 77
TABLE 17 SLIDE STAINER MARKET FOR BLOCKING SERA AND REAGENTS, BY REGION, 2020–2027 (USD MILLION) 78
6.2.3 DILUENTS AND BUFFERS 78
6.2.3.1 Diluents and buffers are used for IHC workflow optimization 78
TABLE 18 SLIDE STAINER MARKET FOR DILUENTS AND BUFFERS, BY REGION, 2020–2027 (USD MILLION) 78
6.2.4 MOUNTING MEDIA, FIXATIVE REAGENTS, AND EMBEDDING MEDIA 79
6.2.4.1 Fixative reagents are used to immobilize antigens and retain cellular and subcellular structures 79
TABLE 19 SLIDE STAINER MARKET FOR MOUNTING MEDIA, FIXATIVE REAGENTS, AND EMBEDDING MEDIA, BY REGION, 2020–2027 (USD MILLION) 79
6.2.5 PROBES 79
6.2.5.1 Probes are widely used in ISH 79
TABLE 20 SLIDE STAINER MARKET FOR PROBES, BY REGION, 2020–2027 (USD MILLION) 80
6.2.6 ANTIBODIES 80
6.2.6.1 Increasing prevalence of infectious diseases and cancer to drive segment growth 80
TABLE 21 SLIDE STAINER MARKET FOR ANTIBODIES, BY REGION, 2020–2027 (USD MILLION) 81
6.3 EQUIPMENT 81
TABLE 22 SLIDE STAINER EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 81
6.3.1 AUTOMATED AND SEMI-AUTOMATED SLIDE STAINERS 81
6.3.1.1 High-throughput efficacy and accuracy of staining biological samples driving segment growth 81
TABLE 23 KEY BRANDS OF AUTOMATED SLIDE STAINERS 82
TABLE 24 AUTOMATED AND SEMI-AUTOMATED SLIDE STAINERS MARKET, BY REGION, 2020–2027 (USD MILLION) 83
6.3.2 MANUAL SLIDE STAINING SETS 83
6.3.2.1 Low cost of manual staining sets to drive segment growth 83
TABLE 25 KEY BRANDS OF MANUAL SLIDE STAINING SETS 83
TABLE 26 MANUAL SLIDE STAINERS MARKET, BY REGION, 2020–2027 (USD MILLION) 84
6.4 CONSUMABLES AND ACCESSORIES 84
TABLE 27 SLIDE STAINER MARKET FOR CONSUMABLES AND ACCESSORIES, BY REGION, 2020–2027 (USD MILLION) 84
7 SLIDE STAINER MARKET, BY APPLICATION 85
7.1 INTRODUCTION 86
TABLE 28 SLIDE STAINER MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 86
7.2 DISEASE DIAGNOSTICS 86
TABLE 29 SLIDE STAINER MARKET FOR DISEASE DIAGNOSTICS, BY DISEASE TYPE, 2020–2027 (USD MILLION) 86
7.2.1 BREAST CANCER 87
7.2.1.1 High prevalence of breast cancer to drive segment growth 87
TABLE 30 BREAST CANCER INCIDENCE, BY REGION, 2020 VS. 2040 87
TABLE 31 SLIDE STAINER MARKET FOR BREAST CANCER, BY REGION, 2020–2027 (USD MILLION) 88
7.2.2 GASTRIC CANCER 88
7.2.2.1 Growing prevalence of and increasing research on gastric cancer to drive segment growth 88
TABLE 32 COLORECTAL CANCER INCIDENCE, BY REGION, 2020 VS. 2040 88
TABLE 33 SLIDE STRAINER MARKET FOR GASTRIC CANCER, BY REGION, 2020–2027 (USD MILLION) 89
7.2.3 LYMPHOMA 89
7.2.3.1 IHC and biopsy are preferable tests to diagnose lymphoma 89
TABLE 34 HODGKIN’S LYMPHOMA INCIDENCE, BY REGION, 2018 VS. 2025 89
TABLE 35 NON-HODGKIN’S LYMPHOMA INCIDENCE, BY REGION, 2018 VS. 2025 90
TABLE 36 SLIDE STAINER MARKET FOR LYMPHOMA, BY REGION, 2020–2027 (USD MILLION) 90
7.2.4 PROSTATE CANCER 90
7.2.4.1 IHC tests are used to identify prostate cancer 90
TABLE 37 PROSTATE CANCER INCIDENCE, BY REGION, 2018 VS. 2025 91
TABLE 38 SLIDE STAINER MARKET FOR PROSTATE CANCER, BY REGION, 2020–2027 (USD MILLION) 91
7.2.5 NON-SMALL CELL LUNG CANCER 91
7.2.5.1 IHC helps analyze adenocarcinoma and squamous carcinoma of lungs through staining of antibodies 91
TABLE 39 NON-SMALL CELL LUNG CANCER INCIDENCE, BY REGION, 2020 VS. 2040 92
TABLE 40 SLIDE STAINER MARKET FOR NON-SMALL CELL LUNG CANCER, BY REGION, 2020–2027 (USD MILLION) 92
7.2.6 OTHER DISEASES 93
TABLE 41 SLIDE STAINER MARKET FOR OTHER DISEASES, BY REGION, 2020–2027 (USD MILLION) 93
7.3 MEDICAL RESEARCH 94
7.3.1 WIDE USE OF TISSUE BIOPSY AND SLIDE STAINING IN DRUG DEVELOPMENT TO DRIVE SEGMENT GROWTH 94
TABLE 42 SLIDE STAINER MARKET FOR MEDICAL RESEARCH, BY REGION, 2020–2027 (USD MILLION) 94
8 SLIDE STAINER MARKET, BY TECHNOLOGY 95
8.1 INTRODUCTION 96
TABLE 43 SLIDE STAINER MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 96
8.2 HEMATOXYLIN & EOSIN (H&E) 96
8.2.1 WIDE USE OF H&E FOR STAINING VARIOUS BIOLOGICAL SAMPLES DRIVING SEGMENT GROWTH 96
TABLE 44 HEMATOXYLIN & EOSIN SLIDE STAINER MARKET, BY REGION, 2020–2027 (USD MILLION) 97
8.3 IMMUNOHISTOCHEMISTRY (IHC) 97
8.3.1 AUTOMATION OF IHC TECHNIQUES DRIVING SEGMENT GROWTH 97
TABLE 45 IMMUNOHISTOCHEMISTRY SLIDE STAINER MARKET, BY REGION, 2020–2027 (USD MILLION) 98
8.4 IN SITU HYBRIDIZATION (ISH) 98
8.4.1 EMERGING ISH STAINING TECHNIQUES SUCH AS FISH AND CISH DRIVING SEGMENT GROWTH 98
TABLE 46 IN SITU HYBRIDIZATION SLIDE STAINER MARKET, BY REGION, 2020–2027 (USD MILLION) 99
8.5 CYTOLOGY 99
8.5.1 WIDE USE OF CYTOLOGY FOR CANCER STUDIES DRIVING SEGMENT GROWTH 99
TABLE 47 CYTOLOGY SLIDE STAINER MARKET, BY REGION, 2020–2027 (USD MILLION) 100
8.6 MICROBIOLOGY 100
8.6.1 INCREASING PREVALENCE OF INFECTIOUS DISEASES DRIVING SEGMENT GROWTH 100
TABLE 48 GLOBALLY REPORTED CASES OF INFECTIOUS DISEASES 101
TABLE 49 MICROBIOLOGY SLIDE STAINER MARKET, BY REGION, 2020–2027 (USD MILLION) 101
8.7 HEMATOLOGY 102
8.7.1 INCREASING PREVALENCE OF HEMATOLOGY DISORDERS DRIVING SEGMENT GROWTH 102
TABLE 50 HEMATOLOGY SLIDE STAINER MARKET, BY REGION, 2020–2027 (USD MILLION) 102
8.8 SPECIAL STAINING 103
8.8.1 SPECIAL STAINING IS USED WHERE ROUTINE H&E TECHNIQUES CANNOT PROVIDE NEEDED INFORMATION 103
TABLE 51 SPECIAL SLIDE STAINERS OFFERED BY SOME PLAYERS 103
TABLE 52 SPECIAL SLIDE STAINER MARKET, BY REGION, 2020–2027 (USD MILLION) 104
9 SLIDE STAINER MARKET, BY END USER 105
9.1 INTRODUCTION 106
TABLE 53 SLIDE STAINER MARKET, BY END USER, 2020–2027 (USD MILLION) 106
9.2 HOSPITALS AND DIAGNOSTIC LABORATORIES 106
9.2.1 NUMBER OF HOSPITALS AND DIAGNOSTIC LABORATORIES INCREASING IN SEVERAL COUNTRIES 106
TABLE 54 SLIDE STAINER MARKET FOR HOSPITALS AND DIAGNOSTIC LABORATORIES, BY REGION, 2020–2027 (USD MILLION) 107
9.3 ACADEMIC AND RESEARCH INSTITUTES 108
9.3.1 INCREASING INVESTMENTS FOR RESEARCH ON DISEASE DIAGNOSIS DRIVING SEGMENT GROWTH 108
TABLE 55 SLIDE STAINER MARKET FOR ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2020–2027 (USD MILLION) 108
9.4 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES 109
9.4.1 INCREASING RESEARCH ON DRUG DISCOVERY TO DRIVE SEGMENT GROWTH 109
TABLE 56 SLIDE STAINER MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2020–2027 (USD MILLION) 109
9.5 OTHER END USERS 109
TABLE 57 ONCOLOGY CONTRACT RESEARCH ORGANIZATIONS 110
TABLE 58 SLIDE STAINER MARKET FOR OTHER END USERS, BY REGION, 2020–2027 (USD MILLION) 110
10 SLIDE STAINER MARKET, BY REGION 111
10.1 INTRODUCTION 112
TABLE 59 SLIDE STAINER MARKET, BY REGION, 2020–2027 (USD MILLION) 112
10.2 NORTH AMERICA 112
FIGURE 30 NORTH AMERICA: CANCER INCIDENCE AND MORTALITY, 2012–2035 113
FIGURE 31 NORTH AMERICA: SLIDE STAINER MARKET SNAPSHOT 113
TABLE 60 NORTH AMERICA: SLIDE STAINER MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 114
TABLE 61 NORTH AMERICA: SLIDE STAINER MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 114
TABLE 62 NORTH AMERICA: SLIDE STAINER REAGENTS AND KITS MARKET, BY TYPE, 2020–2027 (USD MILLION) 114
TABLE 63 NORTH AMERICA: SLIDE STAINER EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 115
TABLE 64 NORTH AMERICA: SLIDE STAINER MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 115
TABLE 65 NORTH AMERICA: SLIDE STAINER MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 115
TABLE 66 NORTH AMERICA: SLIDE STAINER MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION) 116
TABLE 67 NORTH AMERICA: SLIDE STAINER MARKET, BY END USER, 2020–2027 (USD MILLION) 116
10.2.1 US 116
10.2.1.1 US to dominate global slide stainer market 116
TABLE 68 US: CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040 117
TABLE 69 US: KEY MACROINDICATORS 117
TABLE 70 US: SLIDE STAINER MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 118
TABLE 71 US: SLIDE STAINER MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 118
TABLE 72 US: SLIDE STAINER MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 118
TABLE 73 US: SLIDE STAINER MARKET, BY END USER, 2020–2027 (USD MILLION) 119
10.2.2 CANADA 119
10.2.2.1 Increasing prevalence of cancer to drive market growth 119
TABLE 74 CANADA: CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025 119
TABLE 75 CANADA: KEY MACROINDICATORS 120
TABLE 76 CANADA: SLIDE STAINER MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 120
TABLE 77 CANADA: SLIDE STAINER MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 121
TABLE 78 CANADA: SLIDE STAINER MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 121
TABLE 79 CANADA: SLIDE STAINER MARKET, BY END USER, 2020–2027 (USD MILLION) 121
10.3 EUROPE 122
FIGURE 32 EUROPE: CANCER INCIDENCE AND MORTALITY, 2012–2035 122
TABLE 80 EUROPE: SLIDE STAINER MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 123
TABLE 81 EUROPE: SLIDE STAINER MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 123
TABLE 82 EUROPE: SLIDE STAINER REAGENTS AND KITS MARKET, BY TYPE, 2020–2027 (USD MILLION) 123
TABLE 83 EUROPE: SLIDE STAINER EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 124
TABLE 84 EUROPE: SLIDE STAINER MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 124
TABLE 85 EUROPE: SLIDE STAINER MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 124
TABLE 86 EUROPE: SLIDE STAINER MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION) 125
TABLE 87 EUROPE: SLIDE STAINER MARKET, BY END USER, 2020–2027 (USD MILLION) 125
10.3.1 GERMANY 125
10.3.1.1 Increasing cancer screening initiatives to drive market growth 125
TABLE 88 GERMANY: CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025 126
TABLE 89 GERMANY: SLIDE STAINER MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 126
TABLE 90 GERMANY: SLIDE STAINER MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 127
TABLE 91 GERMANY: SLIDE STAINER MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 127
TABLE 92 GERMANY: SLIDE STAINER MARKET, BY END USER, 2020–2027 (USD MILLION) 127
 
10.3.2 FRANCE 128
10.3.2.1 Government funding for cancer diagnosis and prevention to support market growth 128
TABLE 93 FRANCE: CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040 128
TABLE 94 FRANCE: SLIDE STAINER MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 128
TABLE 95 FRANCE: SLIDE STAINER MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 129
TABLE 96 FRANCE: SLIDE STAINER MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 129
TABLE 97 FRANCE: SLIDE STAINER MARKET, BY END USER, 2020–2027 (USD MILLION) 129
10.3.3 UK 130
10.3.3.1 Government initiatives to drive market growth 130
TABLE 98 UK: SLIDE STAINER MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 130
TABLE 99 UK: SLIDE STAINER MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 130
TABLE 100 UK: SLIDE STAINER MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 131
TABLE 101 UK: SLIDE STAINER MARKET, BY END USER, 2020–2027 (USD MILLION) 131
10.3.4 ITALY 131
10.3.4.1 High incidence of cancer to support market growth 131
TABLE 102 ITALY: CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025 132
TABLE 103 ITALY: SLIDE STAINER MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 132
TABLE 104 ITALY: SLIDE STAINER MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 132
TABLE 105 ITALY: SLIDE STAINER MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 133
TABLE 106 ITALY: SLIDE STAINER MARKET, BY END USER, 2020–2027 (USD MILLION) 133
10.3.5 SPAIN 133
10.3.5.1 High incidence of chronic diseases to drive market growth 133
TABLE 107 SPAIN: CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025 134
TABLE 108 SPAIN: SLIDE STAINER MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 134
TABLE 109 SPAIN: SLIDE STAINER MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 135
TABLE 110 SPAIN: SLIDE STAINER MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 135
TABLE 111 SPAIN: SLIDE STAINER MARKET, BY END USER, 2020–2027 (USD MILLION) 135
10.3.6 REST OF EUROPE 136
TABLE 112 LUNG CANCER INCIDENCE IN KEY REST OF EUROPE COUNTRIES, 2020 VS. 2040 136
TABLE 113 LIVER CANCER INCIDENCE IN KEY REST OF EUROPE COUNTRIES, 2020 VS. 2040 137
TABLE 114 ROE: SLIDE STAINER MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 137
TABLE 115 ROE: SLIDE STAINER MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 137
TABLE 116 ROE: SLIDE STAINER MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 138
TABLE 117 ROE: SLIDE STAINER MARKET, BY END USER, 2020–2027 (USD MILLION) 138
 
10.4 ASIA PACIFIC 138
FIGURE 33 ASIA PACIFIC: CANCER INCIDENCE AND MORTALITY, 2012–2035 139
FIGURE 34 ASIA PACIFIC: SLIDE STAINER MARKET SNAPSHOT 140
TABLE 118 APAC: SLIDE STAINER MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 141
TABLE 119 APAC: SLIDE STAINER MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 141
TABLE 120 APAC: SLIDE STAINER REAGENTS AND KITS MARKET, BY TYPE, 2020–2027 (USD MILLION) 141
TABLE 121 APAC: SLIDE STAINER EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 142
TABLE 122 APAC: SLIDE STAINER MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 142
TABLE 123 APAC: SLIDE STAINER MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 142
TABLE 124 APAC: SLIDE STAINER MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION) 143
TABLE 125 APAC: SLIDE STAINER MARKET, BY END USER, 2020–2027 (USD MILLION) 143
10.4.1 JAPAN 143
10.4.1.1 Advanced healthcare infrastructure to support market growth 143
TABLE 126 JAPAN: CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040 144
TABLE 127 JAPAN: SLIDE STAINER MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 144
TABLE 128 JAPAN: SLIDE STAINER MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 144
TABLE 129 JAPAN: SLIDE STAINER MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 145
TABLE 130 JAPAN: SLIDE STAINER MARKET, BY END USER, 2020–2027 (USD MILLION) 145
10.4.2 CHINA 145
10.4.2.1 Increasing healthcare expenditure and funding to drive market growth 145
TABLE 131 CHINA: SLIDE STAINER MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 146
TABLE 132 CHINA: SLIDE STAINER MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 146
TABLE 133 CHINA: SLIDE STAINER MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 146
TABLE 134 CHINA: SLIDE STAINER MARKET, BY END USER, 2020–2027 (USD MILLION) 147
10.4.3 INDIA 147
10.4.3.1 Expanding healthcare sector to drive market growth 147
TABLE 135 INDIA: CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025 147
TABLE 136 INDIA: SLIDE STAINER MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 148
TABLE 137 INDIA: SLIDE STAINER MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 148
TABLE 138 INDIA: SLIDE STAINER MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 149
TABLE 139 INDIA: SLIDE STAINER MARKET, BY END USER, 2020–2027 (USD MILLION) 149
10.4.4 REST OF ASIA PACIFIC 149
TABLE 140 INCIDENCE OF CANCER IN REST OF ASIA PACIFIC 150
TABLE 141 ROAPAC: SLIDE STAINER MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 150
TABLE 142 ROAPAC: SLIDE STAINER MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 151
TABLE 143 ROAPAC: SLIDE STAINER MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 151
TABLE 144 ROAPAC: SLIDE STAINER MARKET, BY END USER, 2020–2027 (USD MILLION) 151
10.5 LATIN AMERICA 152
10.5.1 INCREASING NUMBER OF CANCER SCREENING PROGRAMS TO SUPPORT MARKET GROWTH 152
TABLE 145 LUNG CANCER INCIDENCE IN KEY LATIN AMERICAN COUNTRIES, 2018 VS. 2025 152
TABLE 146 LIVER CANCER INCIDENCE IN KEY LATIN AMERICAN COUNTRIES, 2018 VS. 2025 152
TABLE 147 BREAST CANCER INCIDENCE IN KEY LATIN AMERICAN COUNTRIES, 2018 VS. 2025 153
TABLE 148 LATAM: SLIDE STAINER MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 153
TABLE 149 LATAM: SLIDE STAINER REAGENTS AND KITS MARKET, BY TYPE, 2020–2027 (USD MILLION) 154
TABLE 150 LATAM: SLIDE STAINER EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 154
TABLE 151 LATAM: SLIDE STAINER MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 154
TABLE 152 LATAM: SLIDE STAINER MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 155
TABLE 153 LATAM: SLIDE STAINER MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION) 155
TABLE 154 LATAM: SLIDE STAINER MARKET, BY END USER, 2020–2027 (USD MILLION) 155
10.6 MIDDLE EAST AND AFRICA 156
10.6.1 INCREASING INCIDENCE OF CANCER IN AFRICA TO SUPPORT MARKET GROWTH 156
TABLE 155 AFRICA: CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025 156
TABLE 156 MEA: SLIDE STAINER MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 156
TABLE 157 MEA: SLIDE STAINER REAGENTS AND KITS MARKET, BY TYPE, 2020–2027 (USD MILLION) 157
TABLE 158 MEA: SLIDE STAINER EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 157
TABLE 159 MEA: SLIDE STAINER MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 157
TABLE 160 MEA: SLIDE STAINER MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 158
TABLE 161 MEA: SLIDE STAINER MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION) 158
TABLE 162 MEA: SLIDE STAINER MARKET, BY END USER, 2020–2027 (USD MILLION) 158
 
11 COMPETITIVE LANDSCAPE 159
11.1 OVERVIEW 159
11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 159
TABLE 163 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN SLIDE STAINER MARKET 159
11.3 REVENUE SHARE ANALYSIS 160
FIGURE 35 REVENUE ANALYSIS OF KEY PLAYERS IN SLIDE STAINER MARKET 160
11.4 MARKET SHARE ANALYSIS 161
TABLE 164 SLIDE STAINER MARKET: DEGREE OF COMPETITION 161
11.5 COMPANY EVALUATION MATRIX 162
11.5.1 STARS 162
11.5.2 PERVASIVE PLAYERS 162
11.5.3 EMERGING LEADERS 162
11.5.4 PARTICIPANTS 162
FIGURE 36 SLIDE STAINER MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS 163
11.6 COMPANY EVALUATION MATRIX FOR SMES/START-UPS 164
11.6.1 PROGRESSIVE COMPANIES 164
11.6.2 RESPONSIVE COMPANIES 164
11.6.3 STARTING BLOCKS 164
11.6.4 DYNAMIC COMPANIES 164
FIGURE 37 SLIDE STAINER MARKET: COMPANY EVALUATION MATRIX FOR SMES/ START-UPS 165
11.7 COMPANY FOOTPRINT ANALYSIS 166
11.7.1 REGIONAL FOOTPRINT OF COMPANIES 166
11.7.2 PRODUCT FOOTPRINT OF COMPANIES 167
11.7.3 OVERALL FOOTPRINT OF COMPANIES 168
11.8 COMPETITIVE BENCHMARKING 169
TABLE 165 SLIDE STAINER MARKET: DETAILED LIST OF KEY START-UPS/SMES 169
11.9 COMPETITIVE SCENARIO 170
11.9.1 PRODUCT LAUNCHES/APPROVALS 170
TABLE 166 KEY PRODUCT LAUNCHES 170
11.9.2 DEALS 171
TABLE 167 KEY DEALS 171
11.9.3 OTHER DEVELOPMENTS 172
TABLE 168 OTHER KEY DEVELOPMENTS 172
 
12 COMPANY PROFILES 173
12.1 KEY PLAYERS 173
(Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)*
12.1.1 F. HOFFMANN-LA ROCHE LTD. 173
TABLE 169 F. HOFFMAN-LA ROCHE LTD.: BUSINESS OVERVIEW 173
FIGURE 38 F. HOFFMAN-LA ROCHE LTD.: COMPANY SNAPSHOT (2021) 174
12.1.2 DANAHER 177
TABLE 170 DANAHER: BUSINESS OVERVIEW 177
FIGURE 39 DANAHER: COMPANY SNAPSHOT (2021) 178
12.1.3 PHC HOLDINGS CORPORATION 181
TABLE 171 PHC HOLDINGS CORPORATION: BUSINESS OVERVIEW 181
FIGURE 40 PHC HOLDINGS CORPORATION: COMPANY SNAPSHOT (2021) 182
12.1.4 MERCK KGAA 184
TABLE 172 MERCK KGAA: BUSINESS OVERVIEW 184
FIGURE 41 MERCK KGAA: COMPANY SNAPSHOT (2021) 185
12.1.5 AGILENT TECHNOLOGIES, INC. 188
TABLE 173 AGILENT TECHNOLOGIES, INC.: BUSINESS OVERVIEW 188
FIGURE 42 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2021) 189
12.1.6 ABCAM PLC. 191
TABLE 174 ABCAM PLC.: BUSINESS OVERVIEW 191
FIGURE 43 ABCAM PLC.: COMPANY SNAPSHOT (2021) 192
12.1.7 BECTON, DICKINSON AND COMPANY 194
TABLE 175 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW 194
FIGURE 44 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2021) 195
12.1.8 SIEMENS HEALTHINEERS AG 197
TABLE 176 SIEMENS HEALTHINEERS AG: BUSINESS OVERVIEW 197
FIGURE 45 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2021) 198
12.1.9 SAKURA FINETEK JAPAN CO., LTD. 199
TABLE 177 SAKURA FINETEK JAPAN CO., LTD.: BUSINESS OVERVIEW 199
12.1.10 BIOCARE MEDICAL, LLC 201
TABLE 178 BIOCARE MEDICAL, LLC.: BUSINESS OVERVIEW 201
12.1.11 HARDY DIAGNOSTICS 203
TABLE 179 HARDY DIAGNOSTICS: BUSINESS OVERVIEW 203
12.1.12 GENERAL DATA COMPANY, INC. 204
TABLE 180 GENERAL DATA COMPANY, INC.: BUSINESS OVERVIEW 204
12.1.13 ELITECHGROUP 205
TABLE 181 ELITECHGROUP: BUSINESS OVERVIEW 205
12.1.14 BIOGENEX 206
TABLE 182 BIOGENEX.: BUSINESS OVERVIEW 206
12.1.15 HISTO-LINE LABORATORIES 208
TABLE 183 HISTO-LINE LABORATORIES: BUSINESS OVERVIEW 208
12.1.16 SLEE MEDICAL GMBH 209
TABLE 184 SLEE MEDICAL GMBH: BUSINESS OVERVIEW 209
12.1.17 AMOS SCIENTIFIC PTY LTD. 210
TABLE 185 AMOS SCIENTIFIC PTY LTD.: BUSINESS OVERVIEW 210
*Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.
12.2 OTHER PLAYERS 211
12.2.1 MEDITE MEDICAL GMBH 211
TABLE 186 MEDITE MEDICAL GMBH: COMPANY OVERVIEW 211
12.2.2 CELLPATH LTD. 212
TABLE 187 CELLPATH LTD.: COMPANY OVERVIEW 212
12.2.3 DIAPATH S.P.A. 213
TABLE 188 DIAPATH S.P.A.: COMPANY OVERVIEW 213
12.2.4 BIO SB, INC. 214
TABLE 189 BIO SB, INC.: COMPANY OVERVIEW 214
12.2.5 ROCKLAND IMMUNOCHEMICALS, INC. 214
TABLE 190 ROCKLAND IMMUNOCHEMICALS, INC.: COMPANY OVERVIEW 214
12.2.6 CELL SIGNALING TECHNOLOGY, INC. 215
TABLE 191 CELL SIGNALING TECHNOLOGY, INC.: COMPANY OVERVIEW 215
12.2.7 DIAGNOSTIC BIOSYSTEMS, INC. 216
TABLE 192 DIAGNOSTIC BIOSYSTEMS, INC.: COMPANY OVERVIEW 216
12.2.8 DAKEWE BIOTECHNOLOGY CO., LTD. 217
TABLE 193 DAKEWE BIOTECHNOLOGY CO., LTD.: COMPANY OVERVIEW 217
12.2.9 THERMO FISHER SCIENTIFIC, INC. 218
TABLE 194 THERMO FISHER SCIENTIFIC, INC.: COMPANY OVERVIEW 218
13 APPENDIX 219
13.1 DISCUSSION GUIDE 219
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 223
13.3 AVAILABLE CUSTOMIZATIONS 225
13.4 RELATED REPORTS 225
13.5 AUTHOR DETAILS 226